Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - Deferred ChargesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioXcel Therapeutics (BTAI) EBT (2022 - 2025)

Historic EBT for BioXcel Therapeutics (BTAI) over the last 4 years, with Q3 2025 value amounting to -$18.4 million.

  • BioXcel Therapeutics' EBT rose 55.23% to -$18.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$66.2 million, marking a year-over-year increase of 2477.86%. This contributed to the annual value of -$79.8 million for FY2024, which is 5554.56% up from last year.
  • As of Q3 2025, BioXcel Therapeutics' EBT stood at -$18.4 million, which was up 55.23% from -$19.8 million recorded in Q2 2025.
  • In the past 5 years, BioXcel Therapeutics' EBT ranged from a high of -$13.8 million in Q1 2025 and a low of -$54.3 million during Q4 2022
  • Moreover, its 4-year median value for EBT was -$26.8 million (2024), whereas its average is -$31.8 million.
  • As far as peak fluctuations go, BioXcel Therapeutics' EBT tumbled by 6697.38% in 2023, and later soared by 6341.79% in 2024.
  • Quarter analysis of 4 years shows BioXcel Therapeutics' EBT stood at -$54.3 million in 2022, then surged by 58.84% to -$22.4 million in 2023, then skyrocketed by 36.7% to -$14.2 million in 2024, then decreased by 29.72% to -$18.4 million in 2025.
  • Its last three reported values are -$18.4 million in Q3 2025, -$19.8 million for Q2 2025, and -$13.8 million during Q1 2025.